CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Metamark Genetics, Inc., a privately held molecular diagnostics company developing innovative personalized medicine approaches to optimize cancer care, announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. as Chief Scientific Officer.
Dr. Blume-Jensen joins Metamark with over 20 years of experience in cancer research and oncology drug discovery. From 2001 to 2008 Dr. Blume-Jensen was department head at EMD Serono, Inc. and later at Merck Research Laboratories, Merck & Co, Inc. where he established integrated oncology R&D programs linking therapeutics to patient responder populations. During his tenure he advanced a number of pre-clinical drug programs into the clinic, and provided translational support for clinical programs. Since 2008 he served as Exec. Dir., External Scientific Affairs and Vice President of Daiichi Sankyo Research Institute, Daiichi Sankyo Inc., was 'Therapeutic Area Advisor' for Oncology, and helped formulate a global oncology R&D strategy. Dr. Blume-Jensen's pioneering work on oncogenic signaling, disease mouse models, and more recently efficacy-predictive biomarkers for oncology therapeutics is highly cited. Dr. Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin's laboratory at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral studies in Dr. Tony Hunter's laboratory at the Salk Institute, La Jolla, CA.
Kenneth E. Weg, Metamark's Chairman and CEO stated, "Metamark is very fortunate to have attracted a true leader in the personalized oncology movement to shepherd Metamark's ambitious Research and Development efforts. We welcome Dr. Blume-Jensen to the expanding Metamark team."
Dr. Blume-Jensen stated, "I am very excited about the innovative, function-driven Metamark platform and the opportunity to join the Metamark team to help catapult the launch of the firs
|SOURCE Metamark Genetics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved